Presented by Cheryl Burdette, ND | May 22, 2025 at 11 AM Pacific

As clinicians when we order a lab test, it is generally because we expect a certain result. For example, you may meet with a patient who has significant GI distress and you are relatively sure they will present with some level of pathogenic bacteria, and yet when the stool test is received, the pathogens expected are not there. This does not mean that there was not a positive finding! In this lecture we will review the inflammatory potential of the lack of a healthy microbiome, SCFA and the additional clues sIgA, lactoferrin and other markers give us. We will examine the research that shows interaction with SCFA beyond the blood brain barrier, as well as interactions with beneficial flora, brain health, cardiovascular health and general immune regulation. We will look at the significant impact that microbial deficiencies create and other patterns that emerge from stool testing beyond dysbiosis.

Presented by Heather Hydzik, ND | June 4, 2025 at 12 PM Pacific

Cardiovascular disease is the leading cause of death worldwide yet is often preventable, emphasizing a need for better early screening measures. Major modifiable risk factors such as obesity, metabolic syndrome, hyperlipidemia, hypertension, poor nutrition and sedentary lifestyle are on the rise. While routine laboratory testing like fasting glucose and the lipid panel can fail to identify individuals at high risk of atherosclerosis and insulin resistance, advanced lipid testing and more modern metabolic and inflammatory lab markers can more precisely distinguish high risk patients for whom lifestyle changes and medications could increase lifespan and enhance the proportion of time spent in good health.

Through patient cases, we will discover how assessing levels of oxidized LDL-C, small dense LDL-C, non-HDL-C and apolipoprotein B provides a clearer representation of cardiovascular health than standard markers like LDL-C. Find early evidence of adverse metabolic health with leptin and 1,5-anhydroglucitol. Lastly, we will uncover how fad diets like ketogenic truly impact health. Learn to interpret precision cardiometabolic biomarkers and help patients gain control of their health today.

Learning Objectives:

• Recognize the limitations of standard lipid panels and routine labs, and integrate advanced biomarkers to enhance early detection of cardiometabolic risk and guide personalized treatment strategies.
• Appreciate the contribution of nutrition and lifestyle to the balance between atherogenic and anti-atherogenic lipoproteins, to enable counsel on effective therapies including behavior change, supplementation, and medication.

Presented by Ruth Hobson, ND | June 13, 2025 at 11:05 AM Pacific

Join us for Fullscript Forward, a free, live, virtual event featuring industry leaders driving the future of healthcare and the field of whole person care.

This presentation explores the pathophysiology of breast cancer risk in menopause and introduces the HuMap™, a non-invasive tool for assessing urinary hormones and their metabolites. This presentation will explore phase I and phase II estrogen metabolism, emphasizing the significance of urinary hormone and metabolite testing for uncovering an individual's unique metabolic function. Assessing estrogen metabolite imbalance is a reasonable first step to developing an effective risk reduction strategy for these patients.